ArticleMedicine2025
Endothelial selective adhesion molecule and interleukin-16 play an intermediary role in psoriasis complicated with acute myocardial infarction: A Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a prevalent inflammatory skin disorder, often associated with an increased risk of atherosclerosis. Despite growing evidence suggesting a potential link between psoriasis and acute myocardial infarction (AMI), the causal relationship remains uncertain and is still a subject of debate. This study aims to fill this knowledge gap by utilizing Mendelian randomization (MR) and mediation analysis to systematically evaluate the causal association between psoriasis and AMI. Additionally, we seek to identify potential mediators that may influence this relationship, thereby providing new insights into the underlying mechanisms that could explain the observed association. The psoriasis GWAS dataset (2802 cases, 212,242 controls) was obtained from the FinnGen study, while genetic associations with endothelial selective adhesion molecule (ESAM) and interleukin (IL)-16 levels were derived from meta-analyses by Sun et al (3301 individuals) and Ahola-Olli et al (3483 individuals), respectively. AMI outcome data (3927 cases, 333,272 controls) were extracted from the UK Biobank. Two-sample MR analyses were conducted to assess the causal effects of psoriasis, ESAM, and IL-16 on AMI risk. MR mediation analysis was used to determine whether ESAM and IL-16 mediate the effect of psoriasis on AMI. To minimize the impact of population differences, we employed robust genetic instruments (F > 10) for each exposure, conducted sensitivity analyses (MR-Egger and weighted median) to check for pleiotropy, and ensured the validity of our results across different populations. The genetic liability to psoriasis (odds ratio [OR]: 1.00078; 95% confidence interval [CI]: 1.00008-1.00148; P = .028479), ESAM (OR: 1.00208; 95% CI: 1.00019-1.00397; P = .031089), and IL-16 (OR: 1.00118; 95% CI: 1.00009-1.00227; P = .033826) were associated with higher AMI risks. The proportion of the effects of genetically-predicted psoriasis mediated through genetically-predicted ESMA and IL-16 was 24.8% (95% CI 8.3%-41.2%) and 16.1% (95% CI 5.3%-26.8%), respectively. Genetic liability to psoriasis is correlated with a higher risk of AMI, which is partially mediated by ESAM and IL-16. The targeted intervention of ESAM and IL-16 might help decrease the risk of AMI in psoriasis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.